


- Respond To:
- 523 Dell Street
Bellefonte, PA 16823
 - 44 Universal Rd.
Selinsgrove, PA 17870



Phone: (814) 355-1474 or
(570) 473-7834
Fax: (814) 355-5149
Web: smemsc.org

GUIDELINES FOR USE OF KETAMINE

AGENCY CRITERIA:

1. Each ALS agency requesting to use Ketamine must be a licensed ALS agency in the Commonwealth.
2. Each ALS agency requesting to use Ketamine must have the support of the agency medical director (in writing). This letter must be submitted to the Council/REGIONAL Medical Advisory Committee.
3. The agency must agree to adhere to Statewide ALS Protocol #6003 regarding Musculoskeletal Trauma and/or #8002 regarding Excited Delirium.
4. Ensure that all providers seeking authorization for the use of Ketamine complete the Excited Delirium course #009244 through the PA TRAIN system PRIOR to obtaining authorization from the agency medical director.
5. The agency will ensure that two EMS providers will be at the patient's side before the administration of Ketamine. At least one provider must be an ALS provider above the level of AEMT who has completed the Ketamine education and is authorized by the agency medical director to administer Ketamine. The other provider must be credentialed at the level of EMT or above.
6. Ongoing competence verification will be kept in the agency records
7. The ALS agency must carry an alternative/rescue airway device in various sizes.
8. The ALS agency must have the capability of monitoring and recording the following:
 - i. Continuous waveform capnography in non-intubated patients
 - ii. Continuous ECG
 - iii. Continuous SpO2
 - iv. Blood pressure
 - v. IMCRASS score
9. The agency agrees to notify the Council and Regional MAC when there is a change in leadership and medical direction.

AGENCY MEDICAL DIRECTOR:

1. The agency medical director must submit a letter in support of the agency for use of Ketamine and will perform a QI audit for EACH case where Ketamine was administered.
2. The agency Medical Director will authorize the providers of the requesting agency after successful completion and verification of PA TRAIN Course #009244.
3. The agency medical director will personally assure training and continuing education in patient selection, IMCRASS scoring, considerations of other causes of agitated behavior, continuous respiratory monitoring, advanced airway management, Ketamine pharmacology and use of protocol #8002 (Excited Delirium).
4. The agency medical director will assure initial and ongoing competence for each provider who will use Ketamine.

REGIONAL MEDICAL ADVISORY COMMITTEE:

1. The Regional Medical Advisory Committee must review each agency's request PRIOR to the use of Ketamine by the agency. The regional Medical Director will sign and authorize the agency for use of Ketamine.
2. The Regional QI committee will perform a QI audit of every case when Ketamine is administered for protocol compliance. The results will be forwarded to the RMAC for review as well as the Bureau of EMS for statewide QI.

3. Ketamine may only be carried by approved ALS agencies that adhere to the Excited Delirium protocol #8002 and/or the Musculoskeletal Trauma protocol #6003. Approval will be removed from the agency if either the agency medical director or the Regional Medical Advisory Committee determines there are significant deviations from the protocol.

Agency Medical Director	Print Name	Signature	Date
Agency Manager/Director	Print Name	Signature	Date
Regional Medical Director	Print Name	Signature	Date